Ozanimod is a research area focused on the study of a small molecule drug that acts as a selective modulator of sphingosine 1-phosphate receptor subtypes, particularly S1P1 and S1P5. This drug is being investigated for its potential therapeutic applications in various inflammatory and autoimmune conditions, such as multiple sclerosis, ulcerative colitis, and Crohn's disease. Ozanimod works by reducing the migration of certain immune cells to sites of inflammation, thereby dampening the immune response and reducing tissue damage. Research on ozanimod is ongoing to further understand its mechanisms of action and safety profile in different disease settings.